Fig. 3: SUMOylation affects FOXK2 activity also in MDA-MB-231 cells.
From: SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells
MDA-MB-231 cells were transfected with the empty vector (pCMV5), wild-type FOXK2 and SUMO-mutant FOXK2 vector (K527/633 R) and treated with increasing concentrations of paclitaxel, after which cell viability was assessed by SRB assay (a) and proliferation by clonogenic assay (b). The graphs are representative of three experiments. Statistical significant differences between cells transfected with the wild-type and K527/633 R were determined by Student’s t-test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, significant)
